Venous thromboembolism and radiation therapy: The final radiation-induced thrombosis study analysis

Elisabeth Daguenet, Mathilde Maison, Fabien Tinquaut, Eric-Alban Giroux, Laurent Bertoletti, Jean-Philippe Suchaud, Chloé Rancoule, Jean-Baptiste Guy, Nicolas Magné, Elisabeth Daguenet, Mathilde Maison, Fabien Tinquaut, Eric-Alban Giroux, Laurent Bertoletti, Jean-Philippe Suchaud, Chloé Rancoule, Jean-Baptiste Guy, Nicolas Magné

Abstract

Background: Thromboembolic events frequently complicate the course of malignancy and represent a major cause of morbidity and mortality in cancer patients. In contrast to chemotherapy and other systemic therapies, little is known about the impact of ionizing radiations on the incidence of venous thromboembolism (VTE) in cancer patients.

Methods: In the present prospective study, we aimed to investigate the incidence, management, and outcome of VTE in newly diagnosed cancer patients who received curative radiotherapy.

Results: VTE was found in 8 patients, out of 401 patients at a median time of 80 days after radiotherapy initiation. The incidence rate of VTE at 6 months post-treatment was 2% (95% CI, 0.9-3.7), with 50% of cases occurring during the radiotherapy course and 50% of cases in patients who received or were receiving chemotherapy. As none of the patients harbored a personal history of VTE, no prophylactic measure was initiated during cancer therapy. Most patients received monotherapy with low-molecular-weight heparin and were still on surveillance at the end of the study. No specific clinical risk factor was identified that might systematically indicate the need of thromboprophylaxis in the context of curative radiotherapy.

Conclusions: Although this pan-cancer descriptive study did not relate an increased risk of short-term thrombosis following ionizing radiation, it provides important insight as a basis for future studies with subcategories of cancer, in order to in fine guide further recommendations in frail patients.

Clinical trial registration number: NCT02696447.

Keywords: ionizing radiation; pan-cancer; prophylaxis; radiotherapy; venous thromboembolism.

Conflict of interest statement

The authors have no competing interests.

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Flow diagram. RT, radiotherapy treatment

References

    1. Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22:199‐207.
    1. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer‐associated venous thrombosis. Blood. 2013;122:1712‐1723.
    1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3‐14.
    1. Ay C, Pabinger I, Cohen AT. Cancer‐associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219‐230.
    1. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715‐722.
    1. Hisada Y, Geddings JE, Ay C, Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost. 2015;13:1372‐1382.
    1. Riedl J, Kaider A, Reitter E‐M, et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna cancer and thrombosis study (CATS). Thromb Haemost. 2014;111:670‐678.
    1. Mukai M, Oka T. Mechanism and management of cancer‐associated thrombosis. J Cardiol. 2018;72:89‐93.
    1. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27:4839‐4847.
    1. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16:1153‐1186.
    1. Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699‐728.
    1. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987‐998.
    1. Chargari C, Guy J‐B, Falk AT, et al. Cardiotoxicity research in breast cancer patients: past and future. Am J Cardiol. 2014;113:1447‐1448.
    1. Boyne DJ, Mickle AT, Brenner DR, et al. Long‐term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta‐analysis. Cancer Med. 2018;7:4801‐4813.
    1. Gujral DM, Shah BN, Chahal NS, Senior R, Harrington KJ, Nutting CM. Clinical features of radiation‐induced carotid atherosclerosis. Clin Oncol (R Coll Radiol). 2014;26:94‐102.
    1. Texakalidis P, Giannopoulos S, Tsouknidas I, et al. Prevalence of carotid stenosis following radiotherapy for head and neck cancer: a systematic review and meta‐analysis. Head Neck. 2020;42:1077‐1088.
    1. Guy J‐B, Bertoletti L, Magné N, et al. Venous thromboembolism in radiation therapy cancer patients: findings from the RIETE registry. Crit Rev Oncol Hematol. 2017;113:83‐89.
    1. Guy J‐B, Falk AT, Chargari C, Bertoletti L, Magné N. Thromboembolic events following brachytherapy: case reports. J Contemp Brachytherapy. 2015;7:76‐78.
    1. Cronin‐Fenton DP, Søndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population‐based cohort study in Denmark, 1997‐2006. Br J Cancer. 2010;103:947‐953.
    1. Chen L, Eloranta S, Martling A, et al. Short‐ and long‐term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population‐based register. Radiother Oncol. 2018;126:424‐430.
    1. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601‐609.
    1. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464‐474.
    1. Bouée S, Emery C, Samson A, Gourmelen J, Bailly C, Cotté F‐E. Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database. Thromb J. 2016;14:4.
    1. Sud R, Khorana AA. Cancer‐associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009;123(Suppl 4):S18‐S21.
    1. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004;2:1760‐1765.
    1. Cherkashin MA, Berezina NA. Venous thromboembolism incidence in radiation oncology: retrospective trial. JCO. 2017;35:e18289.
    1. Temraz S, Moukalled N, Gerotziafas GT, et al. Association between radiotherapy and risk of cancer associated venous thromboembolism: a sub‐analysis of the COMPASS‐CAT study. Cancers (Basel). 2021;13:1033.
    1. Bosco C, Garmo H, Adolfsson J, et al. Prostate cancer radiation therapy and risk of thromboembolic events. Int J Radiat Oncol Biol Phys. 2017;97:1026‐1031.
    1. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy‐associated thrombosis. Blood. 2008;111:4902‐4907.
    1. Gerotziafas GT, Taher A, Abdel‐Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS‐cancer‐associated thrombosis study. Oncologist. 2017;22:1222‐1231.
    1. Dickmann B, Ahlbrecht J, Ay C, et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna cancer and thrombosis study. Haematologica. 2013;98:1309‐1314.
    1. Khorana AA, Carrier M, Garcia DA, Lee AYY. Guidance for the prevention and treatment of cancer‐associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:81‐91.
    1. Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566‐e581.
    1. Mandalà M, Falanga A, Roila F, ESMO Guidelines Working Group . Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2011;22 Suppl 6:vi85‐vi92.
    1. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496‐520.
    1. Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta‐analysis. Haematologica. 2019;104:1277‐1287.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する